← Back to Intelligence
// TOPIC PROFILE
3.2.4
Cell Recognition and the Immune System
Analytical deep dive — question counts, mark distribution, mastery curves, command-word breakdowns, and examiner narrative analysis.
Questions
42
Total marks
103
Marks / Q
2.5
Accessibility
62.1%
Mastery
26.9%
Student strength
39.0%
01
At a glance
3.2.4 · Cell Recognition and the Immune System
8YRSYNTHESIS
3.2.4 (Cell Recognition and the Immune System) appeared in 7 of the 8 years between 2017 and 2024, contributing 42 questions and 103 marks across Papers 1, 2 and 3. APPLICATION dominates the mark distribution at 60.2% of total marks. The accessibility–mastery gap sits at 35.2 percentage points (62.1% vs 26.9%) — most students reach partial credit, but full marks remain harder to secure. The largest single question observed is worth 5 marks, signalling that AQA expects complete hierarchical accounts in this sub-section. Mastery varied year-to-year, lowest in 2023 (19.3%) and highest in 2024 (36.8%). Calculation marks are a small share (6.8%) but typically sit at the lower end of the mastery distribution.
Access–mastery gap
+35 pp
Lowest mastery
2023 · 19.3%
Highest mastery
2024 · 36.8%
02
Question type split
By marks · compound to dominant
103MARKS
103
marks
Application60.2%62 marks
Knowledge33.0%34 marks
Calculation6.8%7 marks
(by marks; compound rows assigned to dominant type):
03
Credit terms — quick reference
Mark scheme tier-locked
30TERMS
Tier 1 · Always credit
plasma cellsantibodiesbindagglutinationB cells
Tier 2 · Sometimes credit
memory cellsantigenantibodyphagocytosiscomplementarystandard formreverse transcriptasesubstratecolour changeenzymeantigen-binding siteantigen-antibody complexmitosiscellular responsehumoral response
Reject · Never credit
none specificvirus fuses with lysosomeattacks (for mp2)neutralisecomplementary (for binding)killing toxinactive immunity fast (not comparative)different species of snakeone antibody effective against many antigensvenom amount varies
04
Question patterns
Recurring formats & tariff structure
0PARAGRAPHS
05
Year-over-year presence
P1 + P3 · 2017–2024
8YEARS
| Year | Questions | Total marks | Mean accessibility | Mean mastery |
|---|---|---|---|---|
| 2017 | 3 | 8 | 63.3% | 30.0% |
| 2018 | 8 | 16 | 66.6% | 26.6% |
| 2019 | 4 | 11 | 65.0% | 36.2% |
| 2020 | 5 | 13 | — COVID | — COVID |
| 2021 | 7 | 19 | — COVID | — COVID |
| 2022 | 0 | 0 | — COVID | — COVID |
| 2023 | 11 | 25 | 51.0% | 19.3% |
| 2024 | 4 | 11 | 79.8% | 36.8% |
06
Mark scheme intelligence
2017–2024 mark scheme corpus
35TERMS
Tier 1 — frequently credited
| Term | Times credited | Years | Notes |
|---|---|---|---|
| plasma cells | 5 | 2017, 2018, 2019, 2020, 2024 | |
| antibodies | 4 | 2017, 2019, 2020, 2023 | |
| bind | 3 | 2017, 2018, 2021 | |
| agglutination | 3 | 2017, 2018, 2023 | |
| B cells | 3 | 2018, 2019, 2023 |
Tier 2 — sometimes credited
| Term | Times credited | Years | Notes |
|---|---|---|---|
| memory cells | 3 | 2018, 2020 | |
| antigen | 2 | 2017, 2024 | |
| antibody | 2 | 2017, 2019 | |
| phagocytosis | 2 | 2017, 2018 | |
| complementary | 2 | 2018, 2020 | |
| standard form | 2 | 2018, 2021 | |
| reverse transcriptase | 2 | 2019, 2021 | |
| substrate | 2 | 2019, 2023 | |
| colour change | 2 | 2019, 2023 | |
| enzyme | 2 | 2019, 2023 | |
| antigen-binding site | 2 | 2020 | |
| antigen-antibody complex | 2 | 2020 | |
| mitosis | 2 | 2020, 2023 | |
| cellular response | 2 | 2023 | |
| humoral response | 2 | 2023 |
Commonly rejected language
| Term | Times rejected | Years | Why rejected |
|---|---|---|---|
| none specific | 2 | 2019 | |
| virus fuses with lysosome | 1 | 2017 | |
| attacks (for mp2) | 1 | 2017 | |
| neutralise | 1 | 2018 | |
| complementary (for binding) | 1 | 2018 | |
| killing toxin | 1 | 2018 | |
| active immunity fast (not comparative) | 1 | 2018 | |
| different species of snake | 1 | 2018 | |
| one antibody effective against many antigens | 1 | 2018 | |
| venom amount varies | 1 | 2018 | |
| rabbit safer for animal welfare | 1 | 2018 | |
| same antibody concentration | 1 | 2018 | |
| rabbit produces more per kg | 1 | 2018 | |
| to make sure animal is OK (too vague) | 1 | 2018 | |
| to monitor health (too vague) | 1 | 2018 |
Marks in this sub-section are typically awarded for precise terminology and correct application of biological principles. Sequential mark schemes — where each mark requires building on the previous one — are common in multi-mark questions; stating the first step without progression rarely earns more than one mark. Calculation marks are typically split between method (correct setup and value extraction) and answer (accurate numerical result), allowing partial credit when arithmetic errors occur.
07
Where students lose marks
Examiner-anchored error patterns
4CASE STUDIES
Conceptual errors
- T cells described as producing antibodies — the distinction between T cells and B cells/plasma cells is the most persistent error in this sub-section; it appeared in 2018 Q07.5 and recurs as the primary way mark point 1 is lost in humoral response questions; plasma cells, not T cells, secrete antibodies (2018 P1 Q07.5)
- Antivenom described as a vaccine that triggers an immune response — antivenom contains ready-made antibodies produced by another animal; it does not stimulate the patient's immune system; students who applied the active immunity schema to antivenom scored zero on mechanism and often confused passive with active immunity in the comparison question that followed (2018 P1 Q07.1)
- Antibodies said to destroy the pathogen rather than neutralise the toxin — passive immunity questions test a specific mechanism; neutralising a toxin is not the same as destroying a pathogen, and this distinction determines both what the antibody binds to and which mark points are accessible (2023 P1 Q04.2)
- DNA stated as the genetic material of HIV — this explicitly negates the mark for RNA; students who correctly described the lipid envelope, capsid, and reverse transcriptase lost the most accessible mark in the question by substituting DNA for RNA (2019 P1 Q05.1)
- Non-universal viral features claimed to apply to all viruses — reverse transcriptase and lipid envelopes are present only in some viruses; fewer than 10% correctly identified three universal structural features; bacterial structures including capsule and plasmid appeared frequently (2023 P1 Q01.1)
Vocabulary errors
- "T cell" written without the "helper" qualifier — T helper cells activate B cells; cytotoxic T cells and regulatory T cells do not; the qualifier determines which cells the T cell interacts with and was penalised in 2017 and 2018 (2017 P1 Q07.2)
- "B cell" written instead of "plasma cell" for the antibody-producing cell — plasma cell is the required term; B cell is the precursor; this distinction was flagged in 2024 P3 Q01.1 as the most common error on mark point 4 (2024 P3 Q01.1)
- Binding stated without destruction for antibody mechanism — "the antibody binds the antigen" earns one mark but loses the second; destruction via phagocytosis or agglutination must be included for both marks; this was penalised in 2018 Q07.1 (2018 P1 Q07.1)
- "Active immunity takes time" used as the comparative statement — AQA requires the comparison to be expressed as a relative timescale; "too slow to protect the patient" is accepted; "takes time" alone is insufficiently precise for the comparison mark (2018 P1 Q07.1)
Application errors
- Humoral immune response described in full for a passive immunity question — clonal expansion, antigen presentation, and memory cell formation are active immunity mechanisms; passive immunity involves administering pre-formed antibodies; students who produced detailed correct accounts of active immunity scored zero in 2023 because the question tested an entirely different pathway (2023 P1 Q04.2)
- B cells and T cells listed as cells that stimulate the immune response — the 2023 P3 Q06.1 question asked for cell types that stimulate the response, not cells involved in it; pathogens, infected cells, and cancer cells are the stimulants; B and T cells are components of the response itself; over half of students scored zero (2023 P3 Q06.1)
- "Evaluate" command word ignored — in 2023 P1 Q09.4, most responses addressed only harm done to animals; the command word requires both benefit and harm to be weighed; answering only one side of an evaluate question is penalised consistently across years (2023 P1 Q09.4)
- Data described rather than conclusions drawn — in 2018 P3 Q02.2, students described the scatter graph of CD20 density versus Rituximab effectiveness point-by-point rather than extracting distinct conclusions; only 5% drew three separable conclusions despite most identifying the positive correlation (2018 P3 Q02.2)
High-impact failures · examiner narrative
2018 P1 Q07.53 marks
Tested the humoral immune response in the context of antivenom production by horse immunisation. Only 7.3% achieved full marks. Losses concentrated across three sequential mark points: the idea that B cells with specificity to the venom antigens are selected and proliferate (missed by most); the differentiation of those B cells into plasma cells and memory cells (about half got this); and the second injection producing a faster response at higher antibody concentration (rarely expressed with both qualifiers — "quickly" and "high concentration" were each required, and most students gave only one). T cell and B cell roles were frequently swapped throughout. The question exposed a structural recall failure common in this sub-section: students knew what the immune system does in general terms but not in what sequence and by which specific cell type.
2018 P3 Q02.23 marks5%full marks
Tested the ability to draw conclusions from a scatter graph of CD20 surface protein density versus Rituximab-mediated B cell destruction in chronic lymphocytic leukaemia. Only 5% achieved full marks. The most common failure was describing the positive trend point-by-point rather than drawing three separable conclusions — that Rituximab does not destroy all B cells in any case, that the drug has little effect below approximately 5 arbitrary units of CD20, and that the data do not distinguish cancerous from normal B cell destruction. A secondary failure: some students extrapolated to whether Rituximab should be used at all, rather than staying within the data; the examiner noted that scientific procedures should be assumed ethical unless stated otherwise.
2023 P1 Q04.23 marks
Tested passive immunity via anti-toxin antibody in a disease context, with a figure showing antibody concentration and diarrhoea onset. Fewer than 15% achieved full marks. The critical distinction — that antibodies neutralise the toxin, not destroy the pathogen — was frequently missed; many described antibody-mediated destruction of the pathogen, which is the wrong mechanism and the wrong target. Additionally, the figure was not used by a significant fraction: the question asked which patients should be offered treatment, requiring students to identify from the graph those with the infection but no natural antibody. Students who gave a detailed, accurate account of active immunity scored zero, because the mechanism, timing, and target all differed from what the question tested.
2023 P3 Q06.43 marks8%full marks
Tested use of standard deviation data to draw conclusions about autoimmune disease effects on cellular and humoral immune responses. Only 8% achieved full marks; half scored zero. Failures clustered at three points: students described the statistics correctly and then added "however, no statistical test has been performed so we cannot be sure" — despite SD data being provided specifically for this purpose; responses addressed only cellular or only humoral response, reaching the mark ceiling at 2; and comparisons were made across sex rather than between healthy and autoimmune subjects of the same sex, which the question required. The compound error — having the correct analytical tool and declining to apply it — was noted by the examiner as appearing across multiple years in this sub-section.
08
Difficulty signals
Performance metric synthesis
35PP GAP
Mean accessibility
62.1%
Mean mastery
26.9%
Mean student strength
39.0%
The accessibility–mastery gap of 35.2 percentage points characterises this sub-section's difficulty profile. Most students reach partial credit; full marks remain harder to achieve. Within 3.2 (Cells), 3.2.4 ranks 2 of 4 sub-sections by mean mastery (1 = hardest). Mastery trajectory is broadly flat across the cohort window: 30.0% in 2017 → 36.8% in 2024 (+6.8 percentage points). Mean mastery was lowest in 2023 (19.3%) and highest in 2024 (36.8%).